EUCTR2017-000888-33-FR进行中（未招募）1 期
An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Written informed consent must be obtained before any assessment is performed.
- •Male and female patients between the age of 18-75 (inclusive) at baseline with a diagnosis of PNH based on documented clone size of =10% by RBCs and/or granulocytes, measured by GPI-deficiency on flow cytometry (screening or medical history data acceptable).
- •LDH values = 1.5x upper limit of the normal range for at least 3 pre-SoC dosing measurements taken in relation to 3 different SoC dosing dates over a maximum of 10 weeks prior to Day 1 (screening, baseline or medical history data acceptable). All the screening pre-SoC LDH values > 1x upper limit of normal range (for pre-SoC samples collected at the same day as SoC administration).
- •PNH patients on stable regimen of standard of care complement blockade (monoclonal antibody with anti C5 activity) for at least 3 months prior to first treatment with LNP023.
- •Previous vaccination against Neisseria meningitidis types A, C, Y and W-135 is required at least 4 weeks prior to first dosing with LNP023. Vaccination against N. meningitidis type B should be conducted if available and acceptable by local regulations, at least 4 weeks prior to first dosing with LNP023.
- •Previous vaccination for the prevention of S. pneumoniae and H. influenzae at least 4 weeks prior to first dosing with LNP023.
- •Able to communicate well with the investigator, to understand and comply with the requirements of the study.
- •Other protocol defined inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •Participation in any other investigational drug trial or use of other investigational drugs at the time of enrollment, or within 5 elimination half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
- •Known or suspected hereditary complement deficiency at screening
- •History of hematopoietic stem cell transplantation as verified both at screening and at baseline (unless baseline was skipped)
- •Patients with laboratory evidence of bone marrow failure (reticulocytes <60x10E9/l, platelets <30x10E9/l neutrophils <1x10E9/l) as verified both at screening and at baseline (unless baseline was skipped)
- •A positive HIV test result at screening
- •Presence or suspicion (based on judgment of the investigator) of active infection within 2 weeks prior to first dose of LNP023, or history of severe recurrent bacterial infections
- •History of recurrent meningitis, history of meningococcal infections despite vaccination as verified both at screening and at baseline (unless baseline was skipped)
- •Patients on the immunosuppressive agents such as but not limited to cyclosporine, MMF, tacrolimus, cyclophosphamide, methotrexate less than 8 weeks prior to first treatment with LNP023 unless on a stable regimen for at least 6 3 months prior to first LNP023 dose.
- •Systemic corticosteroids administered at the dose of = 10 mg per day prednisone equivalent within less than 4 weeks prior to first treatment with LNP023
- •Severe concurrent co-morbidities, e.g. patients with severe kidney disease (dialysis), advanced cardiac disease (NYHA class IV), severe pulmonary arterial hypertension (WHO class IV), unstable thrombotic event not amenable to active treatment as judged by the investigator both at screening and at baseline (unless baseline was skipped)
- •Any medical condition deemed likely to interfere with the patient’s participation in the study, or likely to cause serious adverse events during the study
- •Female patients who are pregnant or breastfeeding, or intending to conceive during the course of the study
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception from first dosing with LNP023 until EOS.
- •Other protocol defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
A Study evaluating the safety and efficacy of LNP023 in patients with a blood disorder called paroxysmal nocturnal hemoglobinuria (PNH)EUCTR2017-000888-33-DEovartis Pharma AG15
已完成
不适用
Single-center, open label, multiple dose study to investigate the pharmacokinetics of RO5186582 given BID over 28 days, and in addition, the excretion and metabolism of [13C]- labelled IV microdoses and an oral [14C]-labelled dose of RO5186582 in Healthy Male VolunteersDown Syndrometrisomy 2110083624NL-OMON36981Hoffmann-La Roche6
招募中
1 期
Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131MedDRA version: 21.0Level: PTClassification code: 10059176Term: Juvenile idiopathic arthritis Class: 100000004859juvenile idiopathic arthritisCTIS2023-505844-21-00Galapagos55
进行中（未招募）
1 期
A Study of Nasal Glucagon in Children with Insulin Dependent Diabetessevere hypoglycemiaEUCTR2021-006088-61-Outside-EU/EEAEli Lilly and Company
已完成
不适用
An open label, single dose, single period study to assess the mass balance recovery, metabolite profile and metabolite identification of [14C] APD421 administered via the intravenous route to healthy male subjectsmisselijkheid en brakennauseavomitingNL-OMON42878Acacia Pharma6